LyticGen Pharmaceuticals Files Patent for CRISPR-Enhanced Bacteriophage Therapeutic Targeting MRSA
Dallas biotech secures patent-pending status for VDX-10, a CRISPR-engineered phage therapeutic designed to address critical gaps in MRSA treatment. DALLAS, TX, UNITED STATES, June 12, 2026 /EINPresswire.com/ -- LyticGen Pharmaceuticals, Inc., a …